XML 27 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Goodwill and Other Intangible Assets
 6 Months Ended
Jul. 03, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets GOODWILL AND OTHER INTANGIBLE ASSETS
The following is a rollforward of the Company’s goodwill ($ in millions):
Balance, December 31, 2019
$
22,712.5

Attributable to 2020 acquisitions
10,179.5

Attributable to 2020 divestitures
(180.5
)
Adjustments due to finalization of purchase price allocations
(2.3
)
Foreign currency translation and other
517.9

Balance, July 3, 2020
$
33,227.1

The carrying value of goodwill by segment is summarized as follows ($ in millions):
 
July 3, 2020
 
December 31, 2019
Life Sciences
$
24,033.5

 
$
13,471.8

Diagnostics
6,869.7

 
6,901.2

Environmental & Applied Solutions
2,323.9

 
2,339.5

Total
$
33,227.1

 
$
22,712.5


The increase in the goodwill balance of the Life Sciences segment in the six-month period ended July 3, 2020 is a result of the Cytiva Acquisition. Measurement period adjustments since acquisition reduced the goodwill recognized for the Cytiva Acquisition by approximately $1.3 billion, as the initial allocation of the purchase price was adjusted to allocate additional purchase price to technology, customer relationships, and trade names partially offset by related deferred tax liabilities. Refer to Note 3 for more detail. The Company has not identified any “triggering” events which indicate an impairment of goodwill in 2020.
Finite-lived intangible assets are amortized over their legal or estimated useful life. The following summarizes the gross carrying value and accumulated amortization for each major category of intangible assets ($ in millions):
 
July 3, 2020
 
December 31, 2019
 
Gross Carrying Amount
 
Accumulated Amortization
 
Gross Carrying Amount
 
Accumulated Amortization
Finite-lived intangibles:
 
 
 
 
 
 
 
Patents and technology
$
11,373.8

 
$
(1,136.8
)
 
$
2,712.7

 
$
(934.1
)
Customer relationships, trade names and other intangibles
8,749.1

 
(2,811.1
)
 
6,367.4

 
(2,612.3
)
Total finite-lived intangibles
20,122.9

 
(3,947.9
)
 
9,080.1

 
(3,546.4
)
Indefinite-lived intangibles:
 
 
 
 
 
 
 
Trademarks and trade names
4,269.5

 
—

 
4,216.0

 
—

Total intangibles
$
24,392.4

 
$
(3,947.9
)
 
$
13,296.1

 
$
(3,546.4
)

During the six-month period ended July 3, 2020, the Company acquired finite-lived intangible assets, consisting primarily of developed technology, customer relationships and trade names, with a weighted average life of 17 years as a result of the Cytiva Acquisition. Refer to Note 3 for additional information on the intangible assets acquired.
The Company identified impairment triggers during the first quarter of 2020 which resulted in the impairment of certain long-lived assets, including a trade name. The Company recorded impairment charges totaling $8 million in the six-month period ended July 3, 2020 related to these long-lived assets.